Pharmacotherapy for primary CNS lymphoma: Progress beyond methotrexate?

CNS Drugs

Volumn 25, Issue 6, 2011, Pages 447-457

  Graber, Jerome J ^a   Omuro, Antonio ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antineoplastics; CNS cancer; Lymphoma; Methotrexate; Radiotherapy; Stem cell transplant

Indexed keywords

BORTEZOMIB; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; IBRITUMOMAB TIUXETAN; IBRITUMOMAB TIUXETAN INDIUM 111; IDARUBICIN; IFOSFAMIDE; LOMUSTINE; MANNITOL; METHOTREXATE; METHYLPREDNISOLONE; PIRARUBICIN; PREDNISONE; PROCARBAZINE; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; TEMOZOLOMIDE; TEMSIROLIMUS; TENIPOSIDE; THIOTEPA; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE; VINDESINE;

ADD ON THERAPY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BRAIN LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG FATALITY; DRUG MEGADOSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INFECTION; LOW DRUG DOSE; LUNG TOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; STEM CELL; THROMBOCYTOPENIA;

CENTRAL NERVOUS SYSTEM NEOPLASMS; DRUG THERAPY; HUMANS; LYMPHOMA, NON-HODGKIN; METHOTREXATE; STEM CELL TRANSPLANTATION;

EID: 79958158726     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11589030-000000000-00000     Document Type: Review

References (58)

1. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992; 23: 9-17.
2. Schultz C, Scott C, Sherman W, et al. Preirradiation chemo- therapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 1996; 14: 556-64. (Pubitemid 26051021)
3. O'Neill BP, Wang CH, O'Fallon JR, et al. The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: cognitive function and performance status. North Central Cancer Treatment Group. Neuro Oncol 1999; 1: 196-203.
4. Abrey LE, Yahalom J, DeAngelis LM. Treatment for pri- mary CNS lymphoma: the next step. J Clin Oncol 2000; 18: 3144-50.
5. DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002; 20: 4643-8. (Pubitemid 36025280)
6. DeAngelis LM, Yahalom J, Thaler HT, et al. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992; 10: 635-43.
7. Gabbai AA, Hochberg FH, Linggood RM, et al. High-dose methotrexate for non-AIDS primary central nervous system lymphoma: report of 13 cases. J Neurosurg 1989; 70: 190-4. (Pubitemid 19051713)
8. Omuro AM, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lympho-ma. Arch Neurol 2005; 62: 1595-600. (Pubitemid 41434567)
9. Gavrilovic I, Hormigo A, Kim A, et al. Long-term follow-up of patients with primary central nervous system lymphoma treated with a high-dose methotrexate regimen with or without whole brain radiotherapy [abstract]. Neuro Oncol 2005; 7: 349.
10. O'Brien P, Roos D, Pratt G, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000; 18: 519-26. (Pubitemid 30078533)
11. Bessell EM, Lopez-Guillermo A, Villa S, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002; 20: 231-6. (Pubitemid 34032616)
12. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003; 21: 4483-8. (Pubitemid 46594017)
13. Omuro AM, DeAngelis LM, Yahalom J, et al. Chemo- radiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 2005; 64: 69-74. (Pubitemid 40082939)
14. Korfel A, Martus P, Nowrousian MR, et al. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma. Br J Haematol 2005; 128: 177-83.
15. Ferreri AJM, Dell'Oro S, Foppoli M, et al. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 2006; 66: 1435-8. (Pubitemid 43739659)
16. Shah GD, Yahalom J, Correa DD, et al. Combined im- munochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007; 25: 4730-5. (Pubitemid 350086474)
17. Yamanaka R, Morii K, Shinbo Y, et al. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma. Ann Hematol 2005; 84: 447-55. (Pubitemid 40867921)
18. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrex-ate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009; 374: 1512-20.
19. Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010; 11: 1036-47.
20. Pels H, Schmidt-Wolf IGH, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003; 21: 4489-95. (Pubitemid 46594018)
21. Juergens A, Pels H, Schlegel U, et al. Primary central ner- vous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy - final report. J Neurol 2006; 253: II/23-4.
22. Herrlinger U, Kuker W, Uhl M, et al. NOA-03 trial of high- dose methotrexate in primary central nervous system lym-phoma: final report. Ann Neurol 2005; 57: 843-7. (Pubitemid 40798622)
23. Herrlinger U, Schabet M, Brugger W, et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multi-center trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 2002; 51: 247-52. (Pubitemid 34111448)
24. Batchelor T, Grossman SA, Carson K, et al. Updated results of from NABTT CNS consortium studies in primary CNS lymphoma [abstract]. Ann Oncol 2005; 16: v125.
25. Batchelor T, Carson K, O'Neill A, et al. Treatment of pri- mary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003; 21: 1044-9. (Pubitemid 46594133)
26. Angelov L, Doolittle ND, Kraemer DF, et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol 2009; 27: 3503-9.
27. Omuro A, Taillandier L, Chinot O, et al. Primary CNS lymphoma in younger patients: can whole-brain radiotherapy be deferred? J Neurooncol. Epub 2010 Dec 19.
28. Juergens A, Pels H, Rogowski S, et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 2010; 67: 182-9.
29. Pels H, Juergens A, Glasmacher A, et al. Early relapses in primary CNS lymphoma after response to polychemo-therapy without intraventricular treatment: results of a phase II study. J Neurooncol 2009; 91: 299-305.
30. Norden AD, Drappatz J, Wen PY, et al. Survival among patients with primary central nervous system lymphoma, 1973-2004. J Neurooncol 2011; 101: 487-93.
31. Hoang-Xuan K, Taillandier L, Chinot O, et al. Chemothe- rapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003; 21: 2726-31. (Pubitemid 46606318)
32. Omuro AM, Taillandier L, Chinot O, et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 2007; 85: 207-11. (Pubitemid 47629402)
33. Illerhaus G, Marks R, Muller F, et al. High-dose metho- trexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 2009; 20: 319-25.
34. Zhu JJ, Gerstner ER, Engler DA, et al. High-dose metho- trexate for elderly patients with primary CNS lymphoma. Neuro Oncol 2009; 11: 211-5.
35. Gerstner ER, Zhu JJ, Engler DA, et al. High dose metho- trexate for elderly patients with primary central nervous system lymphoma. Neuro Oncol 2008; 11: 211-5.
36. Panageas KS, Elkin EB, Ben-Porat L, et al. Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer 2007; 110: 1338-44. (Pubitemid 47435607)
37. Nguyen PL, Chakravarti A, Finkelstein DM, et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lym-phoma. J Clin Oncol 2005; 23: 1507-13.
38. Hottinger AF, DeAngelis LM, Yahalom J, et al. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 2007; 69: 1178-82. (Pubitemid 47517564)
39. Plotkin SR, Betensky RA, Hochberg FH, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004; 10: 5643-6. (Pubitemid 39180936)
40. Reni M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 2007; 96: 864-7. (Pubitemid 46452291)
41. Arellano-Rodrigo E, Lopez-Guillermo A, Bessell EM, et al. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 2003; 70: 219-24. (Pubitemid 36469758)
42. Herrlinger U, Brugger W, Bamberg M, et al. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 2000; 54: 1707-8. (Pubitemid 30226828)
43. Reni M, Mason W, Zaja F, et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 2004; 40: 1682-8. (Pubitemid 38902903)
44. Enting RH, Demopoulos A, DeAngelis LM, et al. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004; 63: 901-3. (Pubitemid 39297656)
45. Fischer L, Thiel E, Klasen H-A, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 2006; 17: 1141-5. (Pubitemid 43985251)
46. Wong ET, Tishler R, Barron L, et al. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004; 101: 139-45. (Pubitemid 38812433)
47. Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003; 21: 4151-6. (Pubitemid 46606183)
48. Illerhaus G, Marks R, Ihorst G, et al. High-dose chemo- therapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006; 24: 3865-70. (Pubitemid 46630733)
49. Colombat P, Lemevel A, Bertrand P, et al. High-dose che- motherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006; 38: 417-20. (Pubitemid 44340371)
50. Montemurro M, Kiefer T, Schuler F, et al. Primary central nervous system lymphoma treated with high-dose metho-trexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studien-gruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 2007; 18: 665-71. (Pubitemid 46523269)
51. Illerhaus G, Muller F, Feuerhake F, et al. High-dose che- motherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008; 93: 147-8. (Pubitemid 351156168)
52. Yoon DH, Lee DH, Choi DR, et al. Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. Bone Marrow Transplant 2011; 46: 105-9.
53. Soussain C, Suzan F, Hoang-Xuan K, et al. Results of in- tensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001; 19: 742-9. (Pubitemid 32119089)
54. Cheng T, Forsyth P, Chaudhry A, et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lym-phoma. Bone Marrow Transplant 2003; 31: 679-85. (Pubitemid 36553478)
55. Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 2008; 26: 2512-8.
56. Widemann BC, Balis FM, Kim A, et al. Glucarpidase, leu- covorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol 2010; 28: 3979-86.
57. Iwamoto FM, Schwartz J, Pandit-Taskar N, et al. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer 2007; 110: 2528-34. (Pubitemid 350174940)
58. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007; 25: 1350-6 (Pubitemid 46706881)